> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Designations for 3 Additional Sangamo Products
- URL: https://www.fdaweb.com/fda-approves-designations-for-3-additional-sangamo-products/
- Published: 2017-05-04T12:00:00.000Z
- Updated: 2026-09-14T22:21:45.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138617

FDA has [granted](http://www.marketwatch.com/story/sangamo-therapeutics-announces-special-regulatory-designations-from-the-fda-for-three-clinical-programs-2017-05-04?ref=fdaweb.com) rare pediatric disease designation for Sangamo Therapeutics’ SB-913 *in vivo* genome editing treatment for mucopolysaccharidosis type 2 (MPS 2). It also gave orphan drug designation to the company’s SB-525 cDNA therapy for hemophilia A, and fast-track designation for SB-FIX *in vivo* genome editing treatment for hemophilia B.

The company says that its fourth lead clinical program, SB-318 *in vivo* genome editing treatment for MPS 1, has already received orphan drug and rare pediatric disease designations.